Figure 5

Evaluation of the bioactivity of PRP from patients classified as responders and non-responders using patient-reported outcomes. Responders (resp, green) and non-responders (n-resp, red) to PRP treatment identified using (A) Knee injury and Osteoarthritis Outcome (KOOS JR) Score and (B) Numeric Pain Rating Scale (NPRS) Score in patients with completed questionnaires at baseline (d0) and the 6 weeks (6 wks) and 6 months (6 mo) follow up time-points. For selection of PRP for analyses, patients were categorized as responders or non-responders based on achievement of minimal clinically important difference (MCID) thresholds (dotted lines) of 10-point improvement in KOOS JR and 20% improvement in NPRS at 6 months after PRP injection. Scores are represented as changes relative to self-reported baseline levels (d0) for each patient and each score. RTqPCR analyses of CCL5 mRNA in (C) macrophages and (D) fibroblasts left untreated (Ct) or treated with TNFα (T), PRP (P) or TNFα + PRP (T + P) for 24 h, using PRP from responders or non-responders. RTqPCR data is represented as mean ± S.D (error bars) of 5 (macrophages) and 4 (fibroblasts) independent experiments. **p < 0.01, ****p < 0.0001 by ANOVA followed by Tukey’s post-hoc test. ns = not significant. Graphs were created with GraphPad Prism 8.